Sanofi, searching for new immune system drugs, partners with a young biotech
2023-07-20
并购临床结果高管变更IPO
Dive Brief:
Sanofi is teaming up with a young biotechnology company to discover and develop new oral drugs for diseases tied to the immune system.
Announced Thursday, the alliance between Sanofi and Recludix Pharma specifically revolves around a protein called STAT6, which research suggests plays a role in some respiratory and skin disorders.
Deal terms hold that Recludix will get $125 million in the near term and, potentially, more than $1.2 billion in additional payments if the drugs it advances achieve certain development, regulatory and sales milestones. The biotech could also receive up to double-digit royalties on future sales of any products stemming from the partnership. Sanofi, meanwhile, will have global rights to the medicines that emerge from the collaboration.
Dive Insight:
The success of Dupixent, an inflammation-regulating medicine expected to soon become a megablockbuster, has encouraged Sanofi to continue investing in immunology.
In 2021, for example, the company spent just over a billion dollars to acquire Kymab, a U.K.-based biotech with a drug in mid-stage clinical testing that Sanofi believed had potential to treat a “wide variety of immune-mediated diseases and inflammatory disorders.” Kymab’s drug recently scored positive results in a study testing it in patients with moderate-to-severe eczema.
Within the large branch of research that is immunology, Sanofi has identified dermatology, rheumatology, gastroenterology and respiratory diseases as four priority areas. The company’s latest deal, with its focus on STAT6, may hit on at least two of them.
”Recludix’s approach to targeting STAT6 has significant potential for a number of [immunological and inflammatory] diseases, especially where a precisely tailored oral therapy could best fit within the patient’s needs at various stages of disease,” said Frank Nestle, Sanofi’s chief scientific officer and global head of research, in a statement.
Recludix officially launched in late 2021, equipped with $60 million in funding from a group of investors that included NEA, Westlake Village Partners and Access Biotechnology. The startup was co-founded by Nicholas Lydon, who was also a scientific founder of the cancer drugmaker Blueprint Medicines and played a key role in the development of the targeted therapy Gleevec.
The new Sanofi collaboration “speaks to our ability to successfully solve the challenge of drugging this attractive, yet elusive, therapeutic target,” Whiting said.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。